Camomile Healthcare

camomilehealthcare.com

Our team consists of senior industry professionals who have been involved with creating some of the largest healthcare businesses in India and the region. Some of our recent works include healthcare domain side advisory and due diligence for a US$200 Bn investment firm for acquisition of one of the largest Hospital chains in India and Medical Planning and Operational Strategy for CMC Vellore, a top 5 Academic Medical Institution in Asia for their upcoming 1500 bed facility spread over 1.5 million sq. ft.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

TAIWAN STARTUP MOLSENTECH ULTRA-HIGH SENSITIVITY BIOMEDICAL DETECTION TECHNOLOGY LEAPS ONTO GLOBAL STAGE

Molsentech | July 29, 2022

news image

With its impressive achievements, Molsentech has been selected by the TTA Global Challenge sponsored by Taiwan's Ministry of Science and Technology to participate in US BIO 2022, poised to leverage its introduction to the US market as a stepping stone to leap further into the global stage. The company has successfully launched an electrical based detection system employing ultra-high sensitivity biomedical detection technology that can be applied in various disease detection from an early st...

Read More

Cell and Gene Therapy

PUMA BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ALISERTIB

Puma Biotechnology | September 21, 2022

news image

Puma Biotechnology, Inc. a biopharmaceutical company, announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib h...

Read More

Cell and Gene Therapy, Industrial Impact

BIO-TECHNE ANNOUNCES COMPLETION OF AND GENE THERAPY CATAPULT ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

Bio-Techne Corporation | March 20, 2023

news image

Bio-Techne Corporation announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technolog...

Read More

Research

INSTITUTE FOR BIOSCIENCE AND BIOTECHNOLOGY RESEARCH RECEIVES $16.8 M INVESTMENT FROM THE NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY

Institute for Bioscience and Biotechnology Research | January 14, 2022

news image

The Institute for Bioscience and Biotechnology Research announces a newly funded five-year cooperative agreement with the National Institute of Standards and Technology headed by the Co-Directors of IBBR, Dr. David J. Weber (PI) and Dr. John Marino This award provides more than $3.3 million each year to support groundbreaking research, including technology and standards development that will impact vaccine and therapeutic discovery and development, and to improve access to life-saving treatments...

Read More
news image

Medical

TAIWAN STARTUP MOLSENTECH ULTRA-HIGH SENSITIVITY BIOMEDICAL DETECTION TECHNOLOGY LEAPS ONTO GLOBAL STAGE

Molsentech | July 29, 2022

With its impressive achievements, Molsentech has been selected by the TTA Global Challenge sponsored by Taiwan's Ministry of Science and Technology to participate in US BIO 2022, poised to leverage its introduction to the US market as a stepping stone to leap further into the global stage. The company has successfully launched an electrical based detection system employing ultra-high sensitivity biomedical detection technology that can be applied in various disease detection from an early st...

Read More
news image

Cell and Gene Therapy

PUMA BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ALISERTIB

Puma Biotechnology | September 21, 2022

Puma Biotechnology, Inc. a biopharmaceutical company, announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib h...

Read More
news image

Cell and Gene Therapy, Industrial Impact

BIO-TECHNE ANNOUNCES COMPLETION OF AND GENE THERAPY CATAPULT ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

Bio-Techne Corporation | March 20, 2023

Bio-Techne Corporation announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technolog...

Read More
news image

Research

INSTITUTE FOR BIOSCIENCE AND BIOTECHNOLOGY RESEARCH RECEIVES $16.8 M INVESTMENT FROM THE NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY

Institute for Bioscience and Biotechnology Research | January 14, 2022

The Institute for Bioscience and Biotechnology Research announces a newly funded five-year cooperative agreement with the National Institute of Standards and Technology headed by the Co-Directors of IBBR, Dr. David J. Weber (PI) and Dr. John Marino This award provides more than $3.3 million each year to support groundbreaking research, including technology and standards development that will impact vaccine and therapeutic discovery and development, and to improve access to life-saving treatments...

Read More

Resources

resource image

Cell and Gene Therapy, Industrial Impact

Eliminate Noisy Oxygen Measurements in Bioreactors

Whitepaper

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Eliminate Noisy Oxygen Measurements in Bioreactors

Whitepaper

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us